Concepedia

Maciej Bryl

MB

Statistics

Publications

11

Citations

476

H-Index

10

Active since

2017

Affiliations

Wakayama Medical University(Current)

University of Turin

Vall d'Hebron Hospital Universitari

Dnipro State Medical University

John Paul II Hospital

Maciej Bryl is an author at Wakayama Medical University specializing in oncology, medicine, and pharmacology.

ORCID

Publications per year

2017–2025

11

Publications

11

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Charles M. Rudin, Stephen V. Liu, Ross A. Soo et al. · Journal of Clinical Oncology · 2023 · 107 citations · Full text

, , +14

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

Charles M. Rudin, Stephen V. Liu, Shun Lü et al. · Journal of Clinical Oncology · 2022 · 73 citations

, , +17

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid et al. · Journal of Thoracic Oncology · 2022 · 72 citations · Full text

, , +17

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations

Paweł Krawczyk, Dariusz M. Kowalski, Rodryg Ramlau et al. · Oncology Letters · 2017 · 64 citations · Full text

, , +14

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Niels Reinmuth, Maciej Bryl, Igor Bondarenko et al. · BioDrugs · 2019 · 56 citations · Full text

, , +13

1–5 of 11